Legend Biotech Corporation (LEGN)

From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market opportunity remains robust.

Pre-Market Stock Futures: The futures are trading higher this morning, following a solid bounce-back rally across the major indices on Wednesday, after the worst day for stocks since October. Stocks were headed lower at the open, but as President Trump addressed the audience at the World Economic Forum in Davos, Switzerland, the moment he mentioned... Here Are Thursday's Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More.

Legend Biotech Corporation (LEGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Connective Portfolio Management LLC bought a new stake in Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 24,500 shares of the company's stock, valued at approximately $805,000. Legend Biotech makes

Stock News Fed set for a “hawkish cut”: The Federal Reserve is widely expected to deliver a third 25 bp rate cut amid sharp divisions over inflation vs. job

SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced new long-term clinical and translational data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) from the CARTITUDE-1 and CARTITUDE-4 studies in relapsed / refractory multiple myeloma (RRMM) patients. In triple-class-exposed patients who had received three prior lines of therapy, a median progression-free survival (mPFS) of 50.4 months was observed following a single infusion of CARVYKTI®. This represents one of the longest PFS outcomes reported for a BCMA-targeted CAR-T cell therapy in this heavily pretreated population.

Ensign Peak Advisors Inc trimmed its position in Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) by 30.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,300 shares of the company's stock after selling 2,750 shares during the

Following Legend Biotech's solid financial results for Q3, its average PT rose to $74.90, which implies an upside of about 171.2% from its current stock price. Thanks to increased demand for its "gem" called Carvykti, adjusted net loss decreased by 55.2% to $18.8 million in Q3. A key reason for its growing sales is its superior efficacy compared to Elrexfio, Abecma, and Tecvayli.

31,000-square-foot site expands Legend's U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation

Legend Biotech Corporation ( LEGN ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Jessie Yeung - Vice President of Finance, Investor & Public Relations Ying Huang - CEO & Director Alan Bash - President of CARVYKTI® Carlos Santos - Chief Financial Officer Guowei Fang - President of Research & Development Conference Call Participants Huidong Wang - Barclays Bank PLC, Research Division Terence Flynn - Morgan Stanley, Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division James Shin - Deutsche Bank AG, Research Division Justin Zelin - BTIG, LLC, Research Division Katherine Degen Ashwani Verma - UBS Investment Bank, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech's Third Quarter 2025 Earnings Call.

Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session SOMERSET, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that it will present two oral presentations and seven poster presentations on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for multiple myeloma at the 67th Annual American Society of Hematology (ASH) Annual Meeting taking place from December 6-9, 2025, in Orlando, FL.

SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, November 12, 2025, to review third quarter 2025 results.

The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend Biotech's blood cancer therapy to include a boxed warning for a potentially fatal gastrointestinal condition.

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.